The Priority Review

Tag

IgA Nephropathy

2 stories

  1. Clinical trials

    Novartis registers Phase IIIb trial of zigakibart + atrasentan in primary IgA nephropathy

    This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 340 participants and plans to start December 1, 2026.

  2. Clinical trials

    Results posted for Atacicept study in IgA nephropathy

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blinded, placebo-controlled trial (NCT04716231), enrolled 428 participants and began on June 29, 2023.